INMB INmune Bio

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery
EN
05/10/2020

Underlying

INMBINmune Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INmune Bio

 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Inc. Announces 2025 Results and Provides Business Update

INmune Bio Inc. Announces 2025 Results and Provides Business Update Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update. Recent Corporate Highlights CORDStrom™ Platform: The CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB) is on target to file an MAA submission in the UK mid...

March 30, 2026 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide ...

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.  Conference Call Information To participate in this event, dial approximately ...

March 24, 2026 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzh...

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on the registrational pathway of XPro1595 (“XPro™”) for the treatment of early Alzheimer’s disease on February 27, 2026 at 9:30 a.m. ET. Post the completion of the ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on ...

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET.  The session ...

February 19, 2026 1 EN
 PRESS RELEASE
Free
INMB INMUNE BIO

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registrati...

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune Bio” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it received the official minutes from its End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administrati...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch